Evidence map›Paper›PMID 38298764›Full record

ArticleEuropean urology open science2024

Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Beth Russell, Katharina Beyer, Ailbhe Lawlor, Monique J Roobol, Lionne D F Venderbos, Sebastiaan Remmers, Erik Briers, Sara J MacLennan, Steven MacLennan, Muhammad Imran Omar and 2 more

Abstract read
In one paragraph

Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Beth RussellTranslational Oncology and Urology Research, King's College London, London, UK.
Katharina BeyerDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Ailbhe LawlorTranslational Oncology and Urology Research, King's College London, London, UK.
Monique J RoobolDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Lionne D F VenderbosDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Sebastiaan RemmersDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Erik BriersPatient advocate, Hasselt, Belgium.
Sara J MacLennanAcademic Urology Unit, University of Aberdeen, Aberdeen, UK.
Steven MacLennanAcademic Urology Unit, University of Aberdeen, Aberdeen, UK.
Muhammad Imran OmarAcademic Urology Unit, University of Aberdeen, Aberdeen, UK.
Mieke Van HemelrijckTranslational Oncology and Urology Research, King's College London, London, UK.
PIONEER Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer survivorship was recently identified as a prostate cancer (PCa) research priority by PIONEER, a European network of excellence for big data in PCa. Despite being a research priority, cancer survivorship lacks a clear and agreed definition, and there is a distinct paucity of patient-reported outcome (PRO) data available on the subject. Data collection on cancer survivorship depends on the availability and implementation of (validated) routinely collected patient-reported outcome measures (PROMs). There have been recent advances in the availability of such PROMs. For instance, the European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) is developing survivorship questionnaires. This provides an excellent first step in improving the data available on cancer survivorship. However, we propose that an agreed, standardised definition of (prostate) cancer survivorship must first be established. Only then can real-world data on survivorship be collected to strengthen our knowledge base. With more men than ever surviving PCa, this type of research is imperative to ensure that the quality of life of these men is considered as much as their quantity of life. Patient summary: As there are more prostate cancer survivors than ever before, research into cancer survivorship is crucial. We highlight the importance of such research and provide recommendations on how to carry it out. The first step should be establishing agreement on a standardised definition of survivorship. From this, patient-reported outcome measures can then be used to collect important survivorship data.

Indexed as

Cancer survivorshipPatient-reported outcome measuresProstate cancerQuality of life

Identifiers

PMID38298764
PMCPMC10829596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.